SCHEMBL7079320

SCHEMBL7079320

CCCc1cc(Oc2ccccc2)ccc1OCCOc1ccc2c(c1)OC(CC)(C(=O)O)CC2

nearest known ligand 0.95

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.95
PPARA Q07869 18/20 0.95
PPARD Q03181 3/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081615 0.92 PPARG (0.81) PPARGPPARAPPARD
SCHEMBL7085033 0.92 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7081789 0.92 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7077774 0.91 PPARG (0.79) PPARGPPARAPPARD
SCHEMBL7077775 0.91 PPARG (0.95) PPARGPPARAPPARD
SCHEMBL7077858 0.91 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7083301 0.91 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7081636 0.90 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL7082314 0.89 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL7244058 0.89 PPARG (0.84) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324995-A2 BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS Merck & Co., Inc. (US) 2003-07-09 EP claimed
US-20020082292-A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2002-06-27 US claimed
WO-2002026729-A2 BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS MERCK & CO., INC. (US) 2002-04-04 WO claimed
US-6645997-B2 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma MERCK & CO., INC. 2003-11-11 US disclosed
EP-1324995-A2 BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS Merck & Co., Inc. (US) 2003-07-09 EP disclosed
US-20020082292-A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2002-06-27 US disclosed
WO-2002026729-A2 BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS MERCK & CO., INC. (US) 2002-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082292-A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders PPARD, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.